A more favorable prognosis was observed in responders to first-line therapy who were then actively treated with second-line (24.8 vs. 11.8 months in non-responders, p < 0.001) and third-line chemotherapy (28.9 vs. 17.8 months in non-responders, p = 0.005). Conclusion: Mesothelioma patients benefited from chemotherapy alone only when retreated in the second line after response to first-line therapy.
Introduction
Malignant pleural mesothelioma (MPM) constitutes a health issue associated with an increasing incidence due to widespread past exposure to asbestos in our region and difficulties in management. Generally, MPM shows refractoriness to unimodal therapeutic approaches. A multimodal approach with surgery followed by adjuvant radiotherapy has provided more encouraging results [1] ; nevertheless, the majority of patients with MPM present with inoperable disease. In this case, chemotherapy (CT) is the standard of care [2] . Overall, the median survival time of MPM is low, ranging from 9 to 12 months; however, a small proportion of patients survive longer, irrespective of any active therapy or the presence of Keywords Malignant pleural mesothelioma · Chemotherapy · Surgery · Response · Survival Summary Background: Malignant pleural mesothelioma is a problematic condition due to poor prognosis and difficulties in management. We evaluated the treatment and outcome of 378 mesothelioma patients referred to 6 Italian Oncology Departments. Methods: Demographic and clinical data were collected. Treatment was assessed in terms of chemotherapy (line of treatment, pemetrexedbased regimen, other therapies), surgery, and radiotherapy. Response to therapy, progression-free survival, and overall survival were evaluated. Results: 36 and 342 patients received best supportive care and active treatment, respectively; 86 patients underwent surgery, and 26 received trimodal therapy. Disease control after firstline chemotherapy was achieved in 74.2% of patients (75.7% in patients treated with pemetrexed combined with other drugs and 69% with pemetrexed as monotherapy). The disease control rate was 82.6% in pemetrexed re-challenged individuals. Median survival time was 11.6 months with supportive care, 16.2 months with chemotherapy only, 32.4 months with surgery plus chemotherapy, and 47.2 months with trimodal therapy. recognized demographic and clinical prognostic factors such as age, sex, performance status, tumor morphology, or blood biomarkers [3] [4] [5] .
We describe the characteristics, therapeutic management, and clinical outcomes of a series of 'daily-practice' MPM patients referred to 6 Italian Oncology Departments from March 2002 to January 2014.
Patients and Methods
The clinical records of MPM patients were reviewed. Demographic (sex, age, smoking habits) and clinical data (morphology, Eastern Cooperative Oncology Group Performance Status (ECOG PS), type of treatment, best tumor response to CT) were collected. Treatment was assessed as supportive therapy or CT (first-to third-line treatment, any pemetrexed-based regimens, other therapies). Patients were evaluated according to previous CT, surgery (pleurectomy/decortication (P/D) or extrapleural pneumonectomy (EPP)), or radiotherapy (supportive/antalgic, pleuroscopic access, trimodal combination). Best response was evaluated according to modified RECIST criteria for MPM [6] . Patients with complete response, partial response, or stable disease (SD) were considered responders to therapy. Data were further collected on baseline leukocyte count (WBC, > 8.3 vs. 8. 3 10 9 /l), lactate dehydrogenase (LDH, > 500 vs. 500 U/l), platelet count (PLT, > 400 vs. 400 10 3 /μl), hemoglobin (Hb, < 14 vs. 14 g/dl), and calretinin expression.
The study protocol was approved by the medical ethical committees of the participating centers, and written informed consent was obtained from living patients before study enrollment.
Statistical Analysis
Data were summarized as median (range) for continuous variables and number (%) for categorical variables. Relationships between categorical variables were examined by means of the chi-square test. Treatment was classified as best supportive care (BSC) only, CT only, surgery with CT (± radiotherapy). Odds ratios (OR) for response to therapy and the corresponding 95% confidence intervals (CIs) were computed using multiple logistic regression models. Univariate and multivariate analyses were performed to evaluate the impact of individual and clinical variables on progression-free survival (PFS) and overall survival (OS). PFS was defined as the time from MPM diagnosis until disease progression or death. OS was defined as the time from MPM diagnosis until death from any cause or last follow-up. Patients still alive were censored at the date of the last follow-up or the date last known to be alive. The Kaplan-Meier method was applied to estimate survival probabilities, and the log-rank test was carried out to assess heterogeneity within each prognostic factor. The cumulative 6-, 12-, and 36-month survival probabilities were estimated. Cox's proportional hazards regression model was used to assess the prognostic variables adjusted for the possible confounding effect of all other factors included in the same model. Statistical calculations were performed using the SPSS statistical package version 20 (IBM Corp., Armonk, NY, USA). A two-sided p value of < 0.05 was considered as statistically significant.
Results
A total of 378 patients with available clinical data were analyzed. Patients had a median age of 69.6 years at diagnosis and an ECOG PS of 0-1 (94.2%), and were more likely to be male (74.3%) and have epithelioid MPM (78.8%) (table 1). The diagnosis was made based on histology and cytology in 91.5 and 3.4% of patients, respectively. 5% had a clinical-radiological diagnosis. Data on blood tests were available for a subgroup of patients. Among these, 142/276 (51.4%), 61/276 (22.1%), 167/274 (60.9%), and 19/156 (12.2%) had abnormal WBC, PLT, Hb, and LDH values, respectively. Calretinin expression was available for 75% of patients, and positive expression was found in 98% of epithelioid, 93% of biphasic, and 67% of sarcomatoid MPM.
Treatment
A total of 36 patients received BSC, and 9 of them received radiotherapy. Surgery was performed in 86 (22.7%) patients: 44 had P/D and 42 had EPP. 26 patients underwent postoperative radiotherapy with CT, and the remaining 60 underwent CT only. A pemetrexed-based therapy was given to 92% of patients.
A total of 110 patients underwent supportive/antalgic radiotherapy. 256/342 (75%) patients with active treatment received CT as single modality therapy. Pemetrexed in any combination or as monotherapy was administered as first-line therapy to 94% of these patients. 139 (54.3%) patients received a second-line treatment. Among them, 24 were re-challenged with pemetrexed, whereas the majority (39.6%) was given vinorelbine. 75/256 (29.3%) patients were treated with a third-line therapy, and 15 of them received pemetrexed.
Response to Therapy
Data on best response to first-line CT were available for 244/256 (95.3%) patients with active CT only. 119 of them had SD. Disease control was achieved in 181 (74.2%) patients, and, more specifically, in 75.7% of those treated with pemetrexed combined with other drugs and in 69% of patients with pemetrexed as monotherapy. Disease control after second-line therapy was obtained in 67/129 (51.9%) patients with available data. The rate was 82.6% in pemetrexed re-challenged subjects.
A higher disease control rate after first-line CT was achieved in patients with epithelioid MPM (79.7 vs. 47.4% for sarcomatoid/ mixed; p < 0.001), ECOG PS 0-1 (76 vs. 44.4% ECOG PS 2; p = 0.047), lower PLT ( 400 vs. 400: 80.8 vs. 60%; p = 0.009), and higher Hb levels (> 14 vs. 14: 84.7 vs. 71.3%; p = 0.037). 
Progression-Free Survival
Overall median PFS was 10.2 months (95% CI 9.0-11.5). PFS was higher in patients younger than 70 years (11.6 months, 95% CI 9.8-13.5 vs. 9.1 months, 95% CI 8.1-10.2 for > 70 years; p = 0.025), and in those with epithelioid MPM (11.6 months, 95% CI 10.3-13.0 vs. 6.7 months, 95% CI 4.7-8.7 for sarcomatous/mixed; p = 0.003), ECOG PS 0-1 (10.4 months, 95% CI 9.2-11.5 vs. 5.1 months, 95% CI 2.7-7.5 for ECOG PS 2; p = 0.037), and PLT 400 (10.2 months, 95% CI 8.6-11.8 vs. 
Overall Survival
The median observation time was 17.3 months (range 0.4-141.3 months). During the study period, 304 (80.4%) patients died. For the entire group, the median OS time was 18.7 months (95% CI 16.3-21.1). The 6-and 12-month OS rate was 69 and 52%, respectively. 73 (19.3%) patients survived for more than 3 years. 74% of these patients were younger than 70 years, 87% had epithelioid MPM, 45% underwent surgery, 48% had active CT, and 7% had BSC.
In univariate analysis, patients with age 70 years, epithelioid MPM, and ECOG PS 0-1 showed longer survival. OS was 20.0 months (95% CI 17.1-23.0) for responders or stable none-surgical patients and 9.2 months (95% CI 6.7-11.6) for non-responders (p < 0.001). High PLT and LDH counts and negative calretinin staining were significant negative prognostic factors (table 2) . A longer time to progression was associated with improved OS (31.4 months, 95% CI 27.0-36.0 for subjects with PFS > 12 months vs. 11.0 months, 95% CI 10.1-12.0 for subjects with PFS 12 months; p < 0.001). No association was found with sex and WBC count.
A favorable prognosis was observed in patients undergoing surgery and treated with CT (32.4 months, 95% CI 24.1-40.7) or with trimodal therapy (47.2 months, 95% CI 37.5-56.9). Among patients who did not undergo surgery, no large differences were observed between those receiving BSC (11.6 months, 95% CI 7.2-15.9) and those treated with first-line active CT (16.2 months, 95% CI 14.6-17.8) (table 3, fig. 1 ). No difference was further seen between patients treated in the first line with pemetrexed (16.1 
0-1), therapy (surgery or active CT vs. BSC), LDH (> 500 vs.
500) and PLT (> 400 vs. 400). Overall, mixed/sarcomatous morphology (HR = 1.53, 95% CI 1.09-2.17, p = 0.015), ECOG PS 2 (HR = 2.12, 95% CI 1.16-3.88, p = 0.015), high LDH (HR = 1.44, 95% CI 1.07-1.93, p = 0.015), and high PLT levels (HR = 1.27, 95% CI 1.00-1.60, p = 0.051) were confirmed to be independent negative prognostic factors. Active CT in none-surgical patients was also associated with lower survival (HR = 1.53, 95% CI 1.03-2.26, p = 0.034) (data not shown).
Discussion
We retrospectively evaluated the diagnostic and therapeutic management of 378 MPM patients. First-line CT as single active treatment was administered to 256 patients, and 54% of them were treated in the second line. 16% of patients had surgery with CT, and another 7% received trimodal treatment. Pemetrexed-based CT was administered to 94% of patients with CT only. Disease control was achieved in about 74% of the patients not previously treated with surgery (76% in patients treated with pemetrexed in combination with other drugs and 69% with pemetrexed alone). Generally, these results fall within the wide range reported by other authors with regard to both response rate (11-40% for response and 35-75% for SD) and PFS (9.2 months in our series and 2-8.2 months in the literature) [7] [8] [9] [10] . The median OS of our patients was quite high (18.7 months), while it ranges between 7 and 33 months according to data from population and clinical studies [3, 5, [11] [12] [13] [14] .
It has been shown that response to CT and a longer PFS time are associated with a better prognosis [8, 15, 16] . In our series, the very low number of patients undergoing BSC did not allow for a conclusion to be drawn; however, there was no difference between these patients and those undergoing first-line treatment (16.2 vs. 11.6 months for BSC). Nevertheless, there was a benefit for patients treated in the second or third line having responded to first-line therapy. The benefit was higher for patients retreated with pemetrexed. However, re-challenge with pemetrexed was attempted in patients with sensitive cancers and long PFS. Longer survival was found in patients undergoing surgery (median 36.8 months with P/D and 38.3 months with EPP), and a further advantage was observed for those receiving multimodality therapy, compared with surgical patients not treated with radiotherapy.
As expected, non-epithelial morphology, worse PS, and high PLT were predictive of no response to therapy or proved to be negative prognostic factors [3, 4] . Multivariate analysis did not confirm the independent role of some variables associated with worse survival such as older age and calretinin expression.
MPM treatment is still a challenge, single-modality treatments may not achieve better results than BSC, and a multidisciplinary approach is often required. Treatment was not associated with a significant improvement in survival according to data from a general population [14] , while pemetrexed-based CT is considered the standard first-line treatment in unresectable MPM patients [7, 9, 10, 17] . In everyday clinical practice, a second-line CT is offered at progression. Median survival varies between 10.5 and 13.6 months for re-challenge with a pemetrexed-based therapy, and between 6.2 and 20.8 months in patients treated with other CTs [11, 16, 18] .
Generally, it is suggested that retreatment should be considered in patients achieving an at least 12-month disease control with first-line therapy [16, 18] . Our data seem to support this idea, and, according to our experience, we feel that second-and third-line treatments are inappropriate in patients not responding to firstline therapy.
Surgery can be an option for selected patients with resectable MPM. Median OS in surgically treated patients ranges from 7.1 to 33 months [19] [20] [21] . The benefit of EPP has been questioned, and reanalysis of a large number of studies showed that P/D is associated with a 2.5-fold lower perioperative and short-term (30 days) mortality than EPP [22, 23] . The advantage increases in patients with favorable prognostic predictors when treated with surgery combined with CT and postoperative radiotherapy [20, 24] .
In line with the literature, about 19% of our patients were alive 3 years after their MPM diagnosis. These patients were more likely to have had surgery compared with those who died within 3 years. Indeed, although the prognosis of most MPM patients is poor, a proportion of patients survives longer, irrespective of therapy. Patients enrolled in an Italian population-based survey had a more than 2-year survival of 24%, and there was no significant difference between treated and untreated patients [25] . Another recent study in a general MPM population found that 24% of patients survived more than 20 months, but only 66 and 16% of them had received CT and EPP, respectively [3] . Overall, the percentage of patients surviving more than 3 years was about 10-15% in populationbased studies, growing to 18-68% in patients who underwent surgery [5, 20, 26, 27] .
The aim of this report was to give a picture of the reality faced by MPM patients. As expected, the selection of patients undergoing the various types of therapy (age, histology, etc.) influenced the outcome, and improved survival was observed among patients considered fit for surgery and constituting a more selected population. Nevertheless, the study showed that CT might be ineffective in the first-line setting, and MPM patients benefited from CT alone only when retreated in the second line after a positive response to first-line therapy. Moreover, in accordance with the literature, about 7% had prolonged survival without receiving any active treatment. This group had certain favorable prognostic factors (i.e., younger age at diagnosis, high percentage of epithelioid tumors); nevertheless, there is growing evidence that, like most tumors, MPM is not a single entity but harbors clinico-biological diversity resulting in patients with different molecular profiles or gene expression that may influence survival outcomes [28] .
